WOMED
8.9.2021 07:17:09 CEST | Business Wire | Press release
Womed, the women's health tech company pioneering innovative treatments against challenging uterine pathologies based on a novel polymer material technology, today announced the publication in the Journal of Minimally Invasive Gynecology (JMIG) of results of the clinical trial evaluating its first product, Womed Leaf™. The clinical data demonstrated that the device is safe and effective in preventing intrauterine adhesion in women with uterine fibroids undergoing hysteroscopic myomectomy. Womed also announced that Womed Leaf™ received CE Marking.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210907005710/en/
Intrauterine adhesions (IUAs) occur after 20% to 45% of surgical interventions, when the uterine walls bind together due to abnormal scarring. IUAs are a major cause of infertility and repeated miscarriages. IUA treatment, with a recurrence rate as high as 60%, leaves women unsure and anxious about their chance to conceive.
To prevent IUA formation, ObGyns need to keep the uterine walls separated after an intrauterine intervention. They can use various kinds of gels, but these existing materials become liquid and typically flow out of the cavity too quickly to create an effective barrier. Womed Leaf™ is the first and only mechanical barrier against IUA as it is composed of a soft film that protects the entire uterine cavity for a week and is painlessly discharged naturally afterwards.
Womed LeafTM was evaluated during the first trial of Womed's clinical program, PREG1, which enrolled 23 patients who were scheduled for hysteroscopic myomectomy. Device manipulation was less than two minutes in all cases, and the procedure was described as easy by all operators. None of the study participants suffered any injuries, reactions or adverse events attributable to Womed Leaf. The device caused zero to minimal discomfort to patients and effectively prevented adhesion formation in 83% of women at six weeks.
"We have been impressed with Womed Leaf's ease of use and are now very confident in its safety profile," said Prof. Herve Fernandez, head of the Obstetrics and Gynecology Department at the Bicetre University Hospital, AP-HP, Paris, France. "A mechanical barrier that protects the cavity during the entire healing phase is very compelling compared to our current options."
"Womed Leaf™ represents a major breakthrough in helping women preserve or recover their fertility from the heartbreaking condition of IUA, and we are thrilled by its clinical results and CE Mark approval," said Gonzague Issenmann, co-founder and Executive Chairman of Womed. "We now feel confident to carry out our ambitious strategy: to leverage Womed's proprietary polymer technology and develop a portfolio of unique intrauterine drug delivery products to safely treat challenging uterine pathologies, like acute bleeding and endometriosis."
About WOMED
Womed was founded by health tech entrepreneur Gonzague Issenmann, biomedical polymer specialist Prof. Xavier Garric and reproductive specialist Dr. Stephanie Huberlant, to commercialize an invention from Garric's Polymers for Health and Biomaterials lab at the University of Montpellier, France. Womed's proprietary degradable polymer technology is designed specifically for temporary uterine implantation and controlled drug delivery.
The first product, Womed Leaf™, is a medical device to treat and prevent bonding of the uterine walls after surgical intervention, which is responsible for one in five miscarriages. Womed's pipeline of intrauterine drug delivery products include treatments for acute uterine bleeding and endometriosis.
www.womedtech.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005710/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Plural Raises €1bn to Back the Frontier Founders Building a New Europe16.11.2026 10:00:00 CET | Press release
Plural’s largest raise to date: almost four times its €260m inaugural fund in 2022, and double its €500m second fund in 2024 All former founders and operators, Plural’s partners back founders early to build generational companies that compete globally from Europe Plural’s companies have raised over €3bn in follow-on capital in the last twelve months alone as European tech accelerates Plural, the early-stage investment fund led by founders and operators, has raised €1bn to back the founders Europe is counting on. Plural’s ambition is to have GDP-level impact on Europe. It backs founders building what a changing world needs most over the next decade: energy, AI infrastructure, defence, health and other frontier technologies. For two decades, the bulk of the world’s most valuable technology companies have been built in the US and China, leaving Europe a customer rather than a creator. That has cost the continent prosperity and bargaining power. Rapid technological change now gives Europe
SES and ITU Expand Partner2Connect Digital-learning Initiative to 30 African Schools16.11.2026 09:36:00 CET | Press release
Initiative in Malawi, Burundi, Zambia and Zimbabwe will leverage SES satellite solutions to extend digital learning opportunities to 20,000-30,000 students and teachers. SES, a leading space solutions company, announced progress on its commitment to the International Telecommunication Union's (ITU) Partner2Connect Digital Coalition, through which the company is connecting 30 schools across Malawi, Burundi, Zambia, and Zimbabwe by the end of 2026. The initiative, developed in cooperation with the ITU Telecommunication Development Bureau, aims to expand access to digital education and online resources for an estimated 20,000 to 30,000 students and teachers in underserved and remote communities. Through SES’s solutions, the coalition has given students and educators access to online learning platforms, teacher-training resources and collaboration tools. These resources help schools strengthen digital skills and expand learning opportunities to allow students better participate in the futu
Regnology and ActiveViam Partner to Bring the Same Granular, Explainable Risk Intelligence to Banks and Their Supervisors16.11.2026 09:00:00 CET | Press release
ActiveViam’s Atoti analytics will extend from Regnology Risk Hub to Regnology Supervisory Hub, so the regulated and their regulators can ask their own questions of granular data Regnology, a leading global technology provider at the intersection of regulatory reporting, risk management, finance, and supervisory technology, today announced a strategic partnership with ActiveViam, the provider of Atoti, the AI-native enterprise risk intelligence platform for capital markets. The partnership embeds Atoti as the real-time risk aggregation and analytics engine in Regnology Risk Hub, and will extend it to supervisory authorities through Regnology Supervisory Hub. Regnology is the only provider whose offering serves both the regulated and their regulators, with more than 15,000 financial institutions and more than 100 authorities as clients. Markets and depositors now move within days, and the questions that follow rarely fit a predefined report. During the 2023 market turmoil, supervisors fa
Don’t Let Europe’s Nicotine Black Market Go Unchecked16.11.2026 08:06:00 CET | Press release
Crime Stoppers International asks the public to report illegal vapes and nicotine pouches as organised crime cashes in across Europe. Launched on the UN day against transnational organised crime: the criminals selling black market vapes and nicotine pouches also traffic fake medicine, illicit drugs and weapons. On the UN International Day against Transnational Organised Crime, Crime Stoppers International (CSI) launched Don’t let it go unchecked, a campaign asking the public to help break Europe’s black market in vapes and nicotine pouches by reporting illegal sellers anonymously. This matters more than ever. Illegal vapes and nicotine pouches are flooding into Europe. The sellers don’t care how they’re made or who buys them, and don’t pay taxes. Nobody knows who's behind them, except the criminal networks cashing in. The illegal trade in nicotine products is funding the same criminal networks that traffic fake medicine, illicit drugs and weapons, and putting untested products into the
Sofinnova Partners Closes €725M Crossover II Fund16.11.2026 08:00:00 CET | Press release
Backing late-stage life sciences companies through to clinical development, global expansion and commercialization. Positions Sofinnova to support approximately 15 high-growth companies, primarily in Europe, with selective investments in the U.S. and other markets. Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Crossover II at €725 million ($815 million USD). The fund exceeded its original target, reflecting growing confidence in Sofinnova’s strategy of backing late-stage life sciences companies with the potential to become global leaders. Sofinnova Crossover II will focus primarily on European clinical-stage biopharma and medtech companies seeking capital to advance toward commercialization. It will also invest in best-in-class companies in the United States and other international markets. Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
